MedTrace Logo

Apitox, Honeybee Venom Treatment for Osteoarthritis Pain and Inflammation

NCT00949754 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2010-05-05

No results posted yet for this study

Summary

The study will evaluate Apitox, pure honeybee venom as a treatment for pain and inflammation of osteoarthritis of the knee.

Conditions

  • Osteoarthritis of the Knee

Interventions

DRUG

honeybee venom (Apitoxin (Korea) Apitox (USA))

multiple intradermal injections of 100 ug pure honeybee venom

Sponsors & Collaborators

  • Apimeds, Inc.

    lead INDUSTRY

Principal Investigators

  • Christopher MH Kim, M.D. · Apimeds, CEO

  • Robert Brooks, PhD · Apimeds, Inc, US Chief Operating Officer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
35 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2010-03-31
Completion
2010-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00949754 on ClinicalTrials.gov